dia76ca, I think lower doses of any drug (chemo, radio, immuno) of which the function is to do something that the immune system may notice but is suppressed by PS should be good.
We know that the devastating effects of these drugs are at the basis of infections and side effects that in the end kill you.
So if the immune system doesn't see there is something wrong (because cancer cells are masked) then given Bavi alone will probably not do the trick by lack of sufficient critical mass to activate at the generic level.
So we need SOME agent that will do damage of a kind that gets noticed or that unmasks or flags the cancer cells. But not body wide action, nor on all cells, even health ones.
Bavi will keep PS from suppressing but if the damage to cells is less (but sufficient) then Bavi will be even more successful in targeting PS %-wise.
Of course, how do you sell to a clinical trial patient that he would only receive 50% of the normal dosage of Docetaxel + Bavi versus the full dosage in the control arm. Kind of the world on its head.
Market Data 
Markets 
AI
